HIGHLIGHTS
- who: Yun Li from the (UNIVERSITY) have published the research: Recent advances in therapeutic strategies for triple-negative breast cancer, in the Journal: (JOURNAL) of November/13,/2020
- what: This was a great contribution of Balko and colleagues, who identified the molecular profile of residual TNBC after NAC .
- how: The results showed that 50% (14/28) of patients achieved stable disease and 36% (10/28) had a partial response according to response evaluation criteria . In this trial enzalutamide an AR antagonist that potently plays multiple roles in the AR signaling pathway was tested . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.